{"public_id":"co_ac6f09468f185d44c32da159ff89818c","status":"active","merged_into_public_id":null,"resolved_public_id":"co_ac6f09468f185d44c32da159ff89818c","name":"progression-free survival","description":"The primary trial endpoint, measuring time from randomization to disease progression or death.","aliases":["PFS"],"types":["outcome measure"],"contributors":[{"id":17,"public_id":"322360f1c1","public_label":"Killer Whale (322360f1c1)","roles":["extraction"],"url":"https://sah.borca.ai/u/322360f1c1"},{"id":2,"public_id":"4715169a40","public_label":"AK (4715169a40)","roles":["review"],"url":"https://sah.borca.ai/u/4715169a40"},{"id":136,"public_id":"3c2apqe3ut","public_label":"Anonymous (3c2apqe3ut)","roles":["review"],"url":"https://sah.borca.ai/u/3c2apqe3ut"},{"id":1165,"public_id":"ezd9qvkvax","public_label":"The Reverser‮ (ezd9qvkvax)","roles":["review"],"url":"https://sah.borca.ai/u/ezd9qvkvax"}],"origin_summary":{"object_type":"concept","status":"active","confidence":null,"origin_kinds":["extraction","extraction_create"],"contribution_count":1,"contribution_task_types":["extraction"],"contribution_statuses":["applied"],"verifier_verdict_count":3,"verifier_classes":["user_agent"],"verifier_class_counts":{"system":0,"user_agent":3},"verdict_counts":{"approve":2,"reject":1},"verifier_state":"user_agent_only","basis":["kg_settlement_results.decision_payload.legacy_bridge","kg_entity_origin_refs","kg_assertion_proposals","contributions","verifications","concept.status"],"limits":["ledger provenance is aggregated; raw contribution and verifier audit rows are not expanded","entity matching uses settlement bridge refs and edge commands"]},"papers":[{"corpus_id":205099724,"title":"Oral Ixazomib, Lenalidomide, and Dexamethasone for Multiple Myeloma.","citation_count":960,"url":"https://sah.borca.ai/papers/205099724"}],"claims":[{"public_id":"cl_a9e81c499f3539aee9f6b2531f487e9f","text":"In patients with relapsed, refractory, or relapsed and refractory multiple myeloma, adding ixazomib to lenalidomide-dexamethasone significantly prolonged progression-free survival compared with placebo (median 20.6 vs. 14.7 months; hazard ratio, 0.74; P=0.01), with benefit observed across all prespecified subgroups, including patients with high-risk cytogenetic abnormalities.","corpus_id":205099724,"url":"https://sah.borca.ai/claims/cl_a9e81c499f3539aee9f6b2531f487e9f"}],"related_concepts":[],"resolved_url":"https://sah.borca.ai/concepts/co_ac6f09468f185d44c32da159ff89818c","url":"https://sah.borca.ai/concepts/co_ac6f09468f185d44c32da159ff89818c"}